Supriya Lifesci.

Why is Supriya Lifescience Ltd falling/rising?

As of 21-Jun, Supriya Lifescience Ltd's stock price is at 931.10, reflecting a recent decline due to underperformance against its sector, decreased investor participation, and concerns over long-term growth prospects. Despite a strong monthly performance, these factors are contributing to the current downward trend.

As of 21-Jun, Supriya Lifescience Ltd's stock price is currently at 931.10, reflecting a decrease of 0.8 (-0.09%). The stock has underperformed its sector today by 0.39% and has shown a recent decline of 4.86% over the past week, while the benchmark Sensex has increased by 1.69% during the same period. <BR><BR>Despite a positive performance over the last month, where the stock rose by 28.83% compared to a 2.13% increase in the Sensex, the current price movement indicates a short-term decline. The stock has been gaining for the last two days, with a total increase of 2.01%, but this is overshadowed by the recent weekly performance. <BR><BR>Additionally, there has been a notable drop in investor participation, with delivery volume on June 18 falling by 48.76% against the 5-day average. This decline in trading activity may contribute to the stock's downward pressure. Although the company has demonstrated high management efficiency and is net-debt free, the long-term growth concerns, particularly the slower growth rates in net sales and operating profit, alongside a high valuation compared to peers, may also be influencing investor sentiment negatively. <BR><BR>In summary, the combination of recent underperformance against the sector, declining investor participation, and concerns regarding long-term growth prospects are contributing to the current fall in Supriya Lifescience Ltd's stock price.

Which are the latest news on Supriya Lifesci.?

What does Supriya Lifesci. do?

Supriya Lifescience Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2008, with recent net sales of 206 Cr and a net profit of 50 Cr as of December 2025. Key metrics include a P/E of 37.00 and a market cap of INR 7,949 Cr.

Overview:<BR>Supriya Lifescience Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company on March 26, 2008, after converting from a partnership firm originally established as M/s Supriya Chemicals in 1985. The latest quarterly results reported net sales and net profit for December 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 206 Cr (Quarterly Results - Dec 2025) <BR>Most recent Net Profit: 50 Cr (Quarterly Results - Dec 2025) <BR>Market-cap value: INR 7,949 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.10% <BR>Debt-Equity: -0.06 <BR>Return on Equity: 17.49% <BR>Price to Book: 6.44 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Supriya Lifesci.?

As of 10th June, Supriya Lifescience Ltd has a market capitalization of 7,949.00 Cr, with recent net sales of 735.45 Cr and net profit of 185.28 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Supriya Lifescience Ltd has a market capitalization of 7,949.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 735.45 Cr, while the sum of Net Profit for the same period is 185.28 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds stand at 996.76 Cr, and Total Assets amount to 1,112.31 Cr.

Who are in the management team of Supriya Lifesci.?

The management team of Supriya Lifesci includes Chairman & Managing Director Satish Waman Wagh, Whole-time Directors Smita, Soloni, Shivani Wagh, Balasahab Gulabrao Sawant, and additional independent directors. They oversee the company's operations and strategic direction.

The management team of Supriya Lifesci includes the following individuals:<BR><BR>1. **Satish Waman Wagh** - Chairman & Managing Director<BR>2. **Smita Satish Wagh** - Whole-time Director<BR>3. **Soloni Satish Wagh** - Whole-time Director<BR>4. **Shivani Satish Wagh** - Whole-time Director<BR>5. **Balasahab Gulabrao Sawant** - Whole-time Director<BR>6. **Kedar Shankar Karmarkar** - Independent Director<BR>7. **Bhairav Manojbhai Chokshi** - Independent Director<BR>8. **Dileep Kumar Jain** - Independent Director<BR>9. **Dinesh N Modi** - Independent Director<BR>10. **Neelam Yashpal Arora** - Independent Director<BR>11. **Shweta Shivdhari Singh** - Company Secretary & Compliance Officer<BR>12. **Manoj Deo Dorlikar** - Whole-time Director & Additional Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Supriya Lifesci.?

Peers of Supriya Lifesci. include P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Sanofi India, SPARC, FDC, Aarti Pharma, and Innova Captab. Supriya Lifesci. has a 1-year return of 43.14%, with peers showing varying management risks and capital structures, while SPARC is noted for excellent growth.

Peers: The peers of Supriya Lifesci. are P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Sanofi India, SPARC, FDC, Aarti Pharma, and Innova Captab.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd and Sanofi India, while Good management risk is found at Blue Jet Health and Innova Captab, and Supriya Lifesci. Average management risk is present at Akums Drugs, Strides Pharma, SPARC, FDC, and Aarti Pharma. All peers exhibit Below Average growth except for SPARC, which has Excellent growth, while the rest have Below Average growth. Excellent capital structure is noted at P & G Health Ltd, Supriya Lifesci., Sanofi India, Blue Jet Health, FDC, Aarti Pharma, and Innova Captab, while Good capital structure is seen at Akums Drugs, and Below Average capital structure is present at Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Akums Drugs at 5.85%, while Sanofi India has the lowest at -48.78%. Supriya Lifesci. has a 1-year return of 43.14%, which is significantly higher than Sanofi India but lower than Akums Drugs. Additionally, Sanofi India, FDC, and Aarti Pharma have negative six-month returns.

Should I buy, sell or hold Supriya Lifescience Ltd?

When is the next results date for Supriya Lifescience Ltd?

The next results date for Supriya Lifescience Ltd is 27 May 2026.

The next results date for Supriya Lifescience Ltd is scheduled for 27 May 2026.

Are Supriya Lifescience Ltd latest results good or bad?

Supriya Lifescience Ltd's latest Q2 FY26 results show a strong recovery with a 44.97% increase in net profit and a 37.75% rise in revenue. However, a decline in operating margin raises concerns about ongoing profitability pressures, leading to a mixed overall assessment of the results.

Supriya Lifescience Ltd's latest results for Q2 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹50.43 crore, which is a significant increase of 44.97% quarter-on-quarter (QoQ). Additionally, revenue grew to ₹199.83 crore, reflecting a 37.75% QoQ increase. This indicates a strong recovery from the previous quarter's disappointing results.<BR><BR>However, there are concerns regarding the operating margin, which decreased to 36.35% from 38.96% in the same quarter last year, marking a contraction of 261 basis points. This decline suggests that the company is facing persistent pressures on profitability, likely due to rising input costs and competitive dynamics in the pharmaceutical sector.<BR><BR>Overall, while the recovery in net profit and revenue growth is encouraging, the margin compression raises questions about the sustainability of profitability moving forward. The stock has also underperformed the broader market over the past year, which adds to the cautious outlook. Therefore, the results can be seen as good in terms of growth recovery but bad concerning profitability pressures.

Is Supriya Lifesci. technically bullish or bearish?

As of December 4, 2025, Supriya Lifesci's trend is mildly bullish, supported by mixed indicators such as a bullish weekly MACD and KST, while facing bearish signals on the monthly RSI and Dow Theory showing no clear trend.

As of 4 December 2025, the technical trend for Supriya Lifesci has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart but is bearish on the monthly, suggesting weakening momentum. Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are mildly bullish, reinforcing the short-term positive sentiment. KST is bullish on both weekly and monthly time frames, and OBV is bullish weekly, indicating accumulation. However, Dow Theory shows no trend in both weekly and monthly perspectives. Overall, the current stance is mildly bullish, driven by the mixed indicators, particularly the weekly MACD and KST.

How has been the historical performance of Supriya Lifesci.?

Supriya Lifesci has shown significant growth from March 2020 to March 2025, with net sales increasing from 311.64 Cr to 696.49 Cr, and profit after tax rising from 73.37 Cr to 187.96 Cr. The company's total assets also grew from 336.15 Cr to 1,112.31 Cr, indicating strong overall financial performance.

Answer:<BR>The historical performance of Supriya Lifesci shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Supriya Lifesci's net sales have increased from 311.64 Cr in March 2020 to 696.49 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 311.64 Cr in March 2020 to 696.49 Cr in March 2025. The company's operating profit (PBDIT) has also shown substantial growth, reaching 270.62 Cr in March 2025, up from 109.45 Cr in March 2020. Profit before tax increased from 96.20 Cr in March 2020 to 248.48 Cr in March 2025, while profit after tax rose from 73.37 Cr to 187.96 Cr in the same period. The earnings per share (EPS) improved significantly, from 10.02 in March 2020 to 23.35 in March 2025. On the balance sheet, total assets grew from 336.15 Cr in March 2020 to 1,112.31 Cr in March 2025, with total liabilities increasing from 336.15 Cr to 1,112.31 Cr as well. Cash flow from operating activities improved from 116.00 Cr in March 2020 to 164.00 Cr in March 2025, indicating a positive cash generation trend. Overall, Supriya Lifesci has demonstrated robust growth in sales, profitability, and asset base over the past five years.

Is Supriya Lifesci. overvalued or undervalued?

As of September 18, 2025, Supriya Lifesci. is considered very expensive and overvalued with a PE ratio of 31.26, an EV to EBITDA of 21.96, and a Price to Book Value of 5.59, despite a 10.11% return over the past year, which outperformed the Sensex's 0.08% return.

As of 18 September 2025, the valuation grade for Supriya Lifesci. has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 31.26, an EV to EBITDA of 21.96, and a Price to Book Value of 5.59, all of which suggest that the stock is trading at a premium compared to its earnings and asset values.<BR><BR>In comparison to its peers, Supriya Lifesci. has a higher PE ratio than Sun Pharma (34.46) and a significantly lower PEG ratio of 0.99 compared to Divi's Lab (1.87), which indicates that while growth expectations are considered, the current valuation may not be justified. Additionally, the company's recent stock performance shows a 10.11% return over the past year, outperforming the Sensex's 0.08% return, which may reflect investor optimism despite the overvaluation concerns.

Who are the top shareholders of the Supriya Lifesci.?

The top shareholders of Supriya Lifesci include promoter Satish Waman Wagh with 67.64%, 78 Foreign Institutional Investors holding 7.19%, and individual investors at 16.4%. The highest public shareholder is the Cohesion Mk Best Ideas Sub-trust with 2.06%.

The top shareholders of Supriya Lifesci include the promoters, with Satish Waman Wagh holding the highest stake at 67.64%. There are also 78 Foreign Institutional Investors (FIIs) who collectively hold 7.19% of the company. Additionally, mutual funds are represented by 8 schemes, holding 0.66%. The highest public shareholder is the Cohesion Mk Best Ideas Sub-trust, which holds 2.06%. Individual investors account for 16.4% of the total holdings.

Has Supriya Lifesci. declared dividend?

Yes, Supriya Lifescience Ltd has declared a 40% dividend, amounting to ₹0.80 per share, with an ex-date of September 20, 2024. While the recent total returns have been negative over the last 6 months, the company has shown significant growth in longer periods.

Supriya Lifescience Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: ₹0.80<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.25%, with a dividend return of 0%, resulting in a total return of -10.25%.<BR><BR>Over the past year, the price return was 95.83%, the dividend return was 0.21%, leading to a total return of 96.04%.<BR><BR>In the 2-year period, the price return was 169.88%, the dividend return was 0.56%, culminating in a total return of 170.44%.<BR><BR>For the 3-year period, the price return was 92.15%, with a dividend return of 0.62%, resulting in a total return of 92.77%.<BR><BR>In the 4-year period, both the price and dividend returns were 0%, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, Supriya Lifescience Ltd has declared a dividend, and while the recent total returns show significant growth over longer periods, the short-term performance has been negative. The dividend yield indicates a modest return from dividends relative to the share price.